Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG993

—

651fdf1a-7c25-55a7-af4f-c12c6764c1be

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.426
  • PEROXISOME+0.370
  • ANDROGEN_RESPONSE+0.314
  • BILE_ACID_METABOLISM+0.266
  • MTORC1_SIGNALING+0.256
  • ESTROGEN_RESPONSE_EARLY+0.253
  • GLYCOLYSIS+0.243
  • TGF_BETA_SIGNALING+0.242
  • INTERFERON_ALPHA_RESPONSE+0.241
  • HEME_METABOLISM+0.219

Top 10 suppressed

  • MYC_TARGETS_V2-0.379
  • ALLOGRAFT_REJECTION-0.256
  • WNT_BETA_CATENIN_SIGNALING-0.241
  • E2F_TARGETS-0.221
  • IL6_JAK_STAT3_SIGNALING-0.206
  • OXIDATIVE_PHOSPHORYLATION-0.179
  • G2M_CHECKPOINT-0.157
  • INFLAMMATORY_RESPONSE-0.157
  • SPERMATOGENESIS-0.139
  • TNFA_SIGNALING_VIA_NFKB-0.139

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG1026
mng-umap@100
——0.715
2MNG1104
mng-umap@100
——0.704
3MNG1023
mng-umap@100
——0.704
4MDT-AP-3286
medullo-epn-umap@date-based
MedMedulloblastoma0.699
5MNG1071
mng-umap@100
——0.697
6MNG998
mng-umap@100
——0.695
7TCGA-BH-A0BS-01A-11R-A12P-07
breast-umap@18
—B0.688
8MNG111
mng-umap@100
——0.679
9TCGA-FD-A3SM-01A-11R-A22U-07
bladder-landscape@3
——0.674
10R319
bladder-landscape@3
——0.669

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.426Remibrutinib— uncovered
PEROXISOME0.370Idelalisib— uncovered
ANDROGEN_RESPONSE0.314Inavolisib— uncovered
BILE_ACID_METABOLISM0.266Inavolisib— uncovered
MTORC1_SIGNALING0.256Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.253Inavolisib— uncovered
GLYCOLYSIS0.243Inavolisib— uncovered
TGF_BETA_SIGNALING0.242Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.241Inavolisib— uncovered
HEME_METABOLISM0.219Temsirolimus— uncovered
CHOLESTEROL_HOMEOSTASIS0.208Remibrutinib— uncovered
UV_RESPONSE_DN0.175Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.162Inavolisib— uncovered
ADIPOGENESIS0.153Inavolisib— uncovered
ANGIOGENESIS0.149Remibrutinib— uncovered
MITOTIC_SPINDLE0.141Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.130Idelalisib— uncovered
FATTY_ACID_METABOLISM0.128Inavolisib— uncovered
P53_PATHWAY0.119Idelalisib— uncovered
MYOGENESIS0.117Inavolisib— uncovered